Cassie (Bishop) Markham
Ph.D. Student, GeneticsAbout
Research
Publications
2026
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.
Ge X, Singh J, Li W, Markham C, Ruiz C, Stites E, Bhattacharyya M, Liu Y, Muzumdar M. PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. Cancer Research 2026 PMID: 42095550, DOI: 10.1158/0008-5472.can-25-3625.Peer-Reviewed Original ResearchThis study investigates how PI3K enables pancreatic cancer cells to resist KRAS inhibitors by activating wild-type RAS signaling, suggesting combined PI3K-KRAS targeting as a therapeutic strategy.Baseline cellular state dictates the molecular impact of KRAS mutant variants in pancreatic cancer cells.
Quiñones-Avilés Y, Salovska B, Markham CS, Di Y, Turk BE, Liu Y, Muzumdar MD. Baseline cellular state dictates the molecular impact of KRAS mutant variants in pancreatic cancer cells. BioRxiv 2026 PMID: 41959224, DOI: 10.64898/2026.03.10.710185.Peer-Reviewed Original Research
2023
Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Navarro-Yepes J, Kettner N, Rao X, Bishop C, Bui T, Wingate H, Raghavendra A, Wang Y, Wang J, Sahin A, Meric-Bernstam F, Hunt K, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Research 2023, 83: 3264-3283. PMID: 37384539, PMCID: PMC10592446, DOI: 10.1158/0008-5472.can-23-0705.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerCyclin-dependent kinase 4/6 inhibitorsPatient-derived xenograftsBreast cancerPalbociclib resistanceDisease progressionTherapeutic optionsHR-positive/HER2-negative metastatic breast cancerHormone receptor-positive metastatic breast cancerHER2-negative metastatic breast cancerHormone receptor (HR)-positiveIn vivo patient-derived xenograftPR- breast cancerSensitive to abemaciclibOxidative phosphorylation pathwayPDX-derived organoidsBreast cancer cellsDelay disease progressionStandard of careMechanisms of resistanceMultiple in vitro modelsClinical benefitAbemaciclib treatmentGenetic alterationsCDK4/6is